EX-12.1 4 d493133dex121.htm EX-12.1 EX-12.1

Exhibit 12.1

Catalyst Biosciences, Inc.

Earnings to Fixed Charges Ratio

The following table sets forth the computation of our ratio of earnings to fixed charges and our ratio of earnings to combined fixed charges and preferred dividend requirements for the periods indicated (in thousands):

 

     Nine Months Ended
September 30, 2017
    Year Ended December 31,  
       2016     2015     2014     2013     2012  

Earnings:

            

Net income (loss)

   $ (15,808   $ (16,945   $ (14,762   $ (6,613   $ (9,966   $ (19,073

Fixed charges

     167       217       1,711       341       335       323  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total Deficiency of Earnings

   $ (15,641   $ (16,728   $ (13,051   $ (6,272   $ (9,631   $ (18,750
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Fixed Charges:

            

Interest Expense

   $   $   $ 1,478     $   $   $

Portion of rent expense representative of interest

     167       217       233       341       335       323  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total Fixed Charges

   $ 167     $ 217     $ 1,711     $ 341     $ 335     $ 323  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Ratio of Earnings to Fixed Charges (1)

                        

 

(1) For purposes of computing the ratio of earnings to fixed charges, earnings consist of net income (loss) plus fixed charges. Fixed charges consist of interest expense, amortization of issuance costs and discount or premium related to indebtedness, whether expensed or capitalized, and that portion of rental payments under operating leases we believe to be representative of interest. Earnings were insufficient to cover fixed charges by $15.8 million for the nine months ended September 31, 2017 and $16.9 million, $14.8 million, $6.6 million, $10.0 million and $19.0 million for the years ended December 31, 2016, 2015, 2014, 2013 and 2012, respectively.